Polycystic kidney diseases - Open Access .click

Results 161 to 170 of about 54,096 (252)

Safety and efficacy of the therapy with CD4 + CD25highCD127‐T regulatory cells: When paediatric patient becomes adult

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1392-1402, February 2026.
Abstract Aim CD4 + CD25highCD127‐T regulatory cells (Tregs) remain a drug candidate for immunotherapy of type 1 diabetes. We completed three trials testing Tregs in recently diagnosed type 1 diabetes children. Here, we looked for long‐term safety and efficacy aspects important in the authorisation of this therapy.
Marta Bandura +18 more
wiley +1 more source

Biochemical and Physiological Effects of Galanin in Health and Disease

The FASEB Journal, Volume 40, Issue 2, 31 January 2026.
Galanin is a biologically active neuropeptide hormone that mediates its effects through three galanin receptors. Galanin signaling induces changes in glucose homeostasis amongst others and plays a dynamic role in the physiological health of many organ systems.
Patrick Mireles +3 more
wiley +1 more source

A novel frameshift variation of PKD1 in familial autosomal dominant polycystic kidney diseases: expanding the clinical phenotype and genetic spectrum of PKD1 disorders. [PDF]

BMC Med Genomics
Chen Q, Shi L, Zhu X.
europepmc +1 more source

An extracellular vesicle based hypothesis for the genesis of the polycystic kidney diseases. [PDF]

Extracell Vesicle
Hogan MC, Ward CJ.
europepmc +1 more source

The Case for a Bariatric-Centered Approach to CKD Care [PDF]

, 2019
Friedman, Allon N.
core +1 more source

Medical Management of Polycystic Liver Disease: A Position Statement From the European Reference Network on Hepatological Diseases. [PDF]